



JC03 Rec'd PCT/PTO 1 0 NOV 2005

PCT

DOCKET NO: D0590.70034US01
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DE WILDE
Serial No.: 10/540,634 ✓
Conf. No.: 8371
Int'l Filing Date: December 19, 2003
Title: KINASE SEQUENCES USEFUL FOR DEVELOPING COMPOUNDS FOR
THE PREVENTION AND/OR TREATMENT OF METABOLIC DISEASES
AND NUCLEOTIDE SEQUENCES ENCODING SUCH KINASE
SEQUENCES

Examiner: Not yet assigned
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/8/05


June Watson

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith are the following documents:

- ☒ Information Disclosure Statement
- ☒ PTO 1449 Form with cited references
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
DeWilde, Applicant


John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. D0590.70034US01
Date: November 8, 2005
xNDDx
948845.1



DOCKET NO: D0590.70034US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gert Jules Hector DE WILDE
Serial No.: 10/540,634
Conf. No.: 8371
Int'l Filing Date: December 19, 2003
Title: KINASE SEQUENCES USEFUL FOR DEVELOPING COMPOUNDS
FOR THE PREVENTION AND/OR TREATMENT OF METABOLIC
DISEASES AND NUCLEOTIDE SEQUENCES ENCODING SUCH
KINASE SEQUENCES

Examiner: Not yet assigned
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/8/05

June Watson
June Watson

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

International Search Report from a corresponding PCT Application No. PCT/EP03/14674 (copy enclosed).

GB Search Report for Application No. GB 0230014.3 (copy enclosed).

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

The following are remarks concerning the other information cited:

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.


An early and favorable action is hereby requested.

Respectfully submitted,
De Wilde, Applicant

By: 
John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Telephone: (617) 646-8000

Docket No. D0590.70034US01
Date: November 8, 2005
xNDD



FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/540,634	DOCKET NO.: D0590.70034US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INT'L. FILING DATE: 12/19/03		Confirmation No.: 8371	
		APPLICANT: Gert Jules Hector DeWilde.			
		GROUP ART UNIT: 1645		EXAMINER: Not yet assigned	
Sheet	1	of	2		

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	6,034,228	A	Norris, et al.	03-07-2000

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B1	WO	99/53036	A2	Sugen, Inc.	10-21-1999	
	B2	WO	00/01846	A2	Devgen NV	01-13-2000	
	B3	WO	03/051905	A2	Exelixis, Inc.	06-26-2003	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C1	BERMAN, J, et al., "kin-18, a C. elegans protein kinase involved in feeding," Gene: An Int'l. Journal of Genes and Genomes, Elsevier Science Publishers, Vol. 279, No. 2, 11/28/2001, pgs. 137-147		
	C2	TASSI, et al., "Human JIK, a novel member of the STE20 Kinase family that inhibits JNK and is negatively regulated by Epiderman growth factor," Journal of Biological Chemistry, Vol. 274, No. 47, 11/19/1999, pgs. 33287-33295		
	C3	ZHANG, W., et al., "Cloning of DPK, a novel dendritic cell-derived protein kinase activating the ERK1/ERK2 and KKK/SAPK pathways," Biochemical & Biophysical Research Communications, Vol. 274, No. 3, 08/11/2000, pgs. 872-879		
	C4	MOORE, T.M., et al., "PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization," Journal of Biological Chemistry, Vol. 275, No. 6, 02/11/2000, pgs. 4311-4322		
	C5	HIROSUMI, Jiro, et al., "A central role for JNK in obesity and insulin resistance," Nature, Vol. 420, No. 6913, 11/21/2002, pgs. 333-336		
	C6	OGG, et al., "The fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. Elegans," Nature, MacMillan Journals Ltd., Vol. 389, 10/30/1997, pgs. 994-999		

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/540,634		DOCKET NO.: D0590.70034US01	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INT'L. FILING DATE: 12/19/03		Confirmation No.: 8371	
		APPLICANT: Gert Jules Hector DeWilde.			
		GROUP ART UNIT: 1645		EXAMINER: Not yet assigned	
Sheet	2	of	2		

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C7	HUTCHISON, et al., "Isolation of TAO1, a protein kinase t hat activates MEKs in stress-activated protein kinase cascades," Journal of Biological Chemistry, Vol. 273, No. 44, 10/30/1998, pgs. 28625-28632		
	C8	WILSON, R. et al., "Caenorhabditis elegans putative serine/threonine protein kinase (Sulu) mRNA, complete cds, DB accession no. U32275 (XP002285648)		
	C9	COPE M.J.T.V., KENDRICK-JONES A., "Serine/threonine-protein kinase SULU (EC 2.7.1.37), DB accession no. P46549 (XP002285649)		
	C10	CARTER, T.G., et al., "Homo sapiens serine/threonine kinase (KDS) mRNA, complete cds.," DB accession no. AF181985 (XP002285650)		
	C11	SHIMKETS RA, Leach M, "Human ORFX ORF1427 polypeptide sequence SEQ ID NO:2854," DB accession no. AAB41663 (XP002285651)		
	C12	NAGASE T., et al., "Homo sapiens mRNA for KIAA0881 protein, partial cds," DB accession no. AB020688 (XP002285652)		
	C13	JENKINS SG, et al., "Homo sapiens serine/threonine kinase TAO1 mRNA, complete cds," DB accession no. AY049015 (XP002285653)		
	C14	NAGASE T, et al., "Homo sapiens mRNA for KIAA1361 protein, partial cds," DB accession no. AB037782 (XP002285654)		

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. filed , and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office has waived the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications.]